Fig. 4

NUCB2 was a target of miR-335-5p and acted as an oncogene in LUAD. a Effect of miR-335-5p mimics on the expressions of predicted mRNAs was validated through RT-qPCR. b MiR-335-5p was predicted to possess a binding site on NUCB2. c NUCB2 expression was assessed in LUAD cell lines and BEAS-2B cell line was seen as a control. d RIP assay testified the enrichment of FTX, miR-335-5p and NUCB2 in RISC. e Luciferase activity of NUCB2-WT/Mut in response to the indicated plasmids was certificated via luciferase reporter assay. f NUCB2 knockdown efficacy in H1650 and H1975 cells. g, h The influence of sh-NUCB2 or sh-NC on LUAD cell proliferation was assessed by colony formation and EdU assays. i, j The apoptosis in sh-NUCB2 or sh-NC group was evaluated via flow cytometry analysis and TUNEL assay. k, l Transwell assay was performed to appraise cell migration and invasion in sh-NUCB2 or sh-NC group. m Western blot assay was conducted to evaluate EMT-relevant protein levels in sh-NUCB2 or sh-NC group. **p < 0.01